2015/2016流感季60岁及以上人群中低流感疫苗有效性及既往接种对预防A(H1N1)pdm09或B/Victoria系住院的影响
在西班牙瓦伦西亚地区2015/2016流感季,采用检测阴性设计评估60岁及以上住院患者流感疫苗有效性及既往接种干扰。纳入1049例符合条件的住院患者,187例流感阳性。预防A(H1N1)pdm09住院的调整疫苗有效性为20.2%(95%CI -21.3至47.5%),预防B/Victoria系住院为-33.2%(95%CI -140.1至26.1%)。既往接种季接种与低有效性相关,未接种既往季者非调整有效性较高。
要点
- 2015/2016流感季60岁及以上住院者中,预防A(H1N1)pdm09住院的调整疫苗有效性为20.2%(95%CI -21.3至47.5%)。
- 预防B/Victoria系住院的调整疫苗有效性为-33.2%(95%CI -140.1至26.1%),未观察到效果。
- 既往接种季接种与低疫苗有效性相关;未接种既往季者非调整总体有效性为84.9%(95%CI 9.9至100.0)。
核心结论
- 本研究发现预防A(H1N1)pdm09住院的流感疫苗有效性低,且与既往接种季接种强相关;未观察到预防B/Victoria系住院的效果。
- 2015/2016流感季疫苗有效性低是由于流行病毒与疫苗病毒间的不匹配及不一致。
研究设计与样本
- 研究在瓦伦西亚医院流感研究网络开展主动监测医院为基础的研究,连续收集可能流感相关住院患者的临床和病毒学数据。
- 对合并鼻咽和咽拭子采用逆转录聚合酶链反应分析,并对部分阳性标本进行血凝素测序;通过人口疫苗信息系统确认接种状态。
- 采用检测阴性方法估计流感疫苗有效性;2015-2016流感季共纳入1049例60岁及以上符合条件的住院患者,其中187例流感阳性。
主要发现
- 预防A(H1N1)pdm09住院的调整疫苗有效性为20.2%(95%CI -21.3至47.5%)。
- 预防B/Victoria系住院的调整疫苗有效性为-33.2%(95%CI -140.1至26.1%)。
- 多数A(H1N1)pdm09测序病毒属于新兴6B.1亚分支,由血凝素蛋白S162N和I216T突变定义。
- 限制于既往一年未接种者,非调整总体疫苗有效性为84.9%(95%CI 9.9至100.0),预防A(H1N1)pdm09为77.9%(95%CI -32.7至100.0%),预防B/Yamagata系住院为48.8%(95%CI -219.5至100.0%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The 2015/2016 influenza season was characterized in Europe by the circulation of A(H1N1)pdm09 clade 6B.1 and B/Victoria-lineage influenza viruses. The components of the vaccines used in the current and past two seasons in the Valencia region were similar but not well matched to the 2015/2016 dominant influenza-circulating strains. We estimate influenza vaccine effectiveness (IVE) and interference of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-lineage in this particular season. METHODS: The Valencia Hospital Network for the Study of Influenza runs an active surveillance hospital-based study to collect clinical and virological data from consecutive admissions possibly related to influenza. Combined nasopharyngeal and pharyngeal swabs are analyzed by reverse transcription polymerase chain reaction, and the hemagglutinin is sequenced in a sample of positive influenza specimens. Vaccination is ascertained consulting a population vaccine information system. We estimate IVE using a test-negative approach. RESULTS: During the 2015-2016 season, we recruited 1049 eligible admissions of patients 60 years or older, and 187 tested positive for influenza. The adjusted IVE in preventing admission with A(H1N1)pdm09 was 20.2%; 95% confidence interval (CI) -21.3-47.5% and -33.2%; 95% CI, -140.1-26.1% in preventing admission with B/Victoria-lineage. The majority of A(H1N1)pdm09 sequenced viruses belonged to the emerging 6B.1 subclade, defined by S162N and I216T mutations in the hemagglutinin protein. When we restricted our analysis to those not vaccinated in the previous year, unadjusted IVE was 84.9% (95% CI 9.9-100.0) overall, 77.9% (-32.7-100.0%) in preventing A(H1N1)pdm09 and 48.8% (-219.5-100.0%) in preventing B/Yamagata-lineage admission. CONCLUSIONS: Our findings indicate that IVE was low in preventing A(H1N1)pdm09 and strongly correlated with vaccination in the previous season. No effect in preventing admission with B/Victoria-lineage was observed. For the 2015/2016 season, IVE was low due to a mismatch and lack of concordance between the circulating and vaccine viruses.
引用
- Puig-Barberà J, Guglieri-López B, Tortajada-Girbés M, et al. Low influenza vaccine effectiveness and the effect of previous vaccination in preventing admission with A(H1N1)pdm09 or B/Victoria-Lineage in patients 60 years old or older during the 2015/2016 influenza season. Vaccine. 2017. PMID: 29128380. doi:10.1016/j.vaccine.2017.10.100
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。